New HIV vaccine candidate shows breakthrough promise in preclinical primate study
Click to view quick news summary (Spoiler)
An international scientific collaboration has engineered a novel HIV vaccine candidate that successfully stimulated high levels of rare, broadly neutralizing antibodies in non-human primates, potentially charting a path toward definitive AIDS prevention.
Scientists have developed an experimental HIV vaccine candidate that has shown highly encouraging results in preclinical studies, raising fresh hopes of preventing new HIV infections by triggering the production of rare, broadly neutralizing antibodies capable of fighting the virus despite its rapid mutations, researchers announced. The vaccine, jointly developed by scientists from the La Jolla Institute for Immunology (LJI), Scripps Research, and the International AIDS Vaccine Initiative (IAVI), holds the long-awaited potential to protect global populations from developing HIV infection and AIDS. According to LJI, it stands as the first HIV vaccine candidate to successfully generate a high level of broadly neutralizing, virus-fighting antibodies in primates.
“This feels like a huge success,” said Shane Crotty, chief scientific officer at LJI, who co-led the research initiative alongside Scripps Research professor William Schief. “We constructed a successful vaccine from the ground up, which required a deep and foundational understanding of the immune system.”
Understanding B Cell Maturation
The vaccine works by directly targeting a biological process known as B cell maturation. B cells are specialized immune cells responsible for producing targeted antibodies. Like many components of the human immune system, they begin their life cycle in a naive stage before expanding into cells capable of generating antibodies. Once B cells detect an invading pathogen, such as a virus, they begin maturing after recognizing specific parts of the pathogen’s unique molecular structure, producing antibodies that can securely bind to those structures and effectively prevent an ongoing infection.
Researchers explained that B cells often require significant time to identify the most vulnerable molecular targets on a moving pathogen. As they continually mature, they refine the structure of the antibodies they produce, enabling them to bind more effectively to those vulnerable sites.
The Complex Obstacles of HIV
Historically, HIV has proved particularly difficult to defeat because it actively prevents B cells from developing effective antibodies. The first major challenge is that the virus expertly disguises itself from the immune response by surrounding its exterior with constantly shifting sugar molecules, known as glycans, allowing it to evade detection by host immune cells that are also naturally covered with glycans.
The second challenge involves HIV’s extraordinary, unchecked ability to mutate. “The worldwide diversity of HIV mutations is extraordinary. Even the diversity within one individual person living with HIV is dramatic,” explained Patrick Madden, an LJI instructor who served as study co-first author along with Jon Steichen, an investigator at Scripps Research.
The third obstacle is the virus’s unique ability to physically change its shape while actively infecting human cells. Even if B cells manage to recognize a specific part of the virus, its structure changes rapidly, rendering previously produced antibodies entirely ineffective. Taken together, these characteristics rarely give naive B cells enough opportunity to develop potent neutralizing antibodies before the virus establishes a permanent foothold.
Reversing the Immune Response
The LJI and Scripps Research teams spent years carefully identifying rare, broadly neutralizing antibodies capable of binding to HIV by recognizing critical viral structures that remain stable even when other parts of the virus mutate. Although these antibodies are extremely uncommon, they have been isolated in blood samples from a small number of people living with chronic HIV infection.
Researchers noted that any truly effective HIV vaccine would need to stimulate a healthy immune system to produce these exact same broadly neutralizing antibodies. “How could we flip the whole immune response on its head so the rare responses become the common responses? That was a critical challenge we faced,” Crotty emphasized.
To solve this, scientists examined what made these specific HIV-targeting B cells unique before tracing their complete maturation process in reverse. This enabled them to determine how B cells evolved after being exposed to specific components of HIV’s structure. The team discovered that B cells successfully developed broadly neutralizing antibodies after early exposure to stable portions of HIV’s outer envelope protein. These specific viral regions, known as antigens because they trigger immune responses, became the basis for designing the vaccine.
A Moon Mission for Medicine
The Schief laboratory subsequently engineered vaccine molecules that closely resembled these critical HIV antigens. The final vaccine candidate was then tested in rhesus macaques at the Emory National Primate Research Center. The researchers found that about 44% of the animals successfully produced broadly neutralizing antibodies against HIV, with the antibodies present in substantial quantities.
The findings, published in the journal Nature, represent the ultimate culmination of 14 years of intense collaboration between the La Jolla Institute for Immunology and Scripps Research as part of the Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD). “This has been one of those Apollo moon mission-type projects, where there is an exceptional goal and the team has to accomplish a myriad of discoveries and inventions along the way,” Crotty concluded.
